The exciting results derived from these phase III trials indicated that ICIs contributed to improving the survival of NSCLC patients without targetable mutations; however, ICI monotherapy exerts limited benefit in those with EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.